{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fneurologypodcast.simplecast.com%2Fepisodes%2Ftd-management-options-rNT9rTIJ","width":444,"version":"1.0","type":"rich","title":"Pharmacologic Management Options for Patients With Tardive Dyskinesia","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/2e5234ff-73b5-430c-81f8-529e0b63a7bb/sy-tardive-dyskinesia-podcast-icon-3.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/5d5c3562-ffef-405a-97bd-f55c4131b03f\" height=\"200\" width=\"100%\" title=\"Pharmacologic Management Options for Patients With Tardive Dyskinesia\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management."}